Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released Thursday by the House Committee on Oversight and Reform.

For the same time period, the report notes that the companies’ top executives earned more as they raised drug prices, with salaries growing by 14% and compensation totaling $3.2 billion. In addition, findings show research and development budgets were spent “on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research.”
 

Related News Articles

Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation,…
Headline
The Campaign for Sustainable Rx Pricing (CSRxP), of which the AHA is a founding member, today launched new television and digital advertising encouraging…